JSJagoda Szkudlarek

Jagoda Szkudlarek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jagoda Szkudlarek has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    20-Hydroxyecdysone-Loaded Niosomes as a Novel Nano-Therapeutic Platform for Psoriasis: In Vitro Characterization and Danio rerio Toxicity Studies

    by Ludwika Piwowarczyk, Jagoda Szkudlarek, Dariusz T. Mlynarczyk, Szymon Tomczak, Violetta Krajka-Kuźniak, Aleksandra Majchrzak-Celińska, Robert Kleszcz, Ewelina Musielak, Mateusz de Mezer, Emilia Cicha, et al.

    Background/Objectives: Psoriasis is an incurable chronic immune-mediated inflammatory skin disorder for which effective topical treatment remains essential. Given the reported anti-inflammatory and dermatological potential of 20-hydroxyecdysone (20HE), this study evaluated its biological activity in normal and psoriatic keratinocytes and developed stable 20HE-loaded niosomes intended for potential future dermal delivery. Methods: The biological activity of 20HE was assessed in human epidermal keratinocytes (HEKs) and psoriasis-patient-derived keratinocytes (PHEKs) after 48 h of treatment by quantifying selected cytokines. Niosomes were prepared by thin-film hydration, rehydrated with water or citrate buffer, and sonicated. The formulations were characterized for particle size, polydispersity index, zeta potential, pH, encapsulation efficiency (EE), and 21-day storage stability. Potential in vivo toxicity was assessed in Danio rerio embryos by monitoring mortality, sublethal developmental changes, and locomotor behavior after exposure to nanoformulations for up to 96 h post-fertilization. Results: 20HE showed selective anti-inflammatory activity in PHEK cells, reducing IL-4, IL-17A, and IL-22 levels by 20–34% under elevated inflammatory conditions, without affecting healthy HEK cells. The formulations had particle sizes below 300 nm and acceptable polydispersity and zeta potential values, and they remained stable during storage. In the Danio rerio embryo model, the 1A/water caused sublethal developmental abnormalities at 96 hpf, whereas 1C/water (with 20HE) was associated only with mild pericardial edema after prolonged exposure. No significant behavioral alterations were observed across the tested concentration range, and the Lowest Observed Effect Concentration for 20HE was 20 μM. Conclusions: Free 20HE reduced the levels of IL-4, IL-17A, and IL-22 in PHEK cells, indicating its modulatory effect on cytokine production under the investigated inflammatory conditions. The developed 20HE-loaded niosomes showed favorable physicochemical properties and short-term stability, supporting their potential as candidate nanocarrier systems for future dermal application studies. The findings of the present study provide a basis for further investigation, particularly studies on drug release from the niosomal formulation and skin permeation from the final pharmaceutical dosage form.

  • Open Access

    Cannabidiol in Gliomas: Therapeutic Potential and Nanocarrier Strategies, with an Emphasis on Vesicular Delivery Systems

    by Jagoda Szkudlarek, Ludwika Piwowarczyk, Anna Jelińska

    Cannabidiol (CBD), a nonpsychoactive phytocannabinoid extracted from Cannabis sativa, has emerged as a compound of considerable therapeutic interest across numerous medical disciplines, including pain management, anti-inflammatory therapy, and oncology. This review critically examines the potential of CBD in the treatment of glioblastoma multiforme (GBM), one of the most aggressive and treatment-resistant primary brain tumors. Particular emphasis is placed on the molecular mechanisms underlying CBD's antitumor activity, including the modulation of key signaling pathways, inhibition of tumor proliferation, and enhancement of chemosensitivity. Furthermore, the review highlights the increasing role of nanotechnology in overcoming the intrinsic pharmacokinetic limitations of CBD, particularly its low oral bioavailability, which presents a significant challenge to its clinical application. Advanced nanocarrier platforms, including nanoemulsions, nanoparticles, nanoparticle-based transdermal systems, nanocapsules, and liposomes, have shown promise in optimizing CBD delivery to the central nervous system (CNS). Notably, the integration of CBD into lipid-based drug delivery systems (LBDDS) is highlighted as a particularly promising strategy to potentiate its therapeutic efficacy. This approach enhances bioavailability and may amplify synergistic effects when combined with conventional chemotherapeutics or targeted agents. Overall, the synergistic use of nanotechnological approaches and CBD-based therapies may open new avenues for research, offering the potential to significantly advance treatment efficacy in glioblastoma and other diseases.


  • Open Access

    Liposomal Co-Delivery of Acteoside, CBD, and Naringenin: A Synergistic Strategy Against Gliomas

    by Jagoda Szkudlarek, Ludwika Piwowarczyk, Violetta Krajka-Kuźniak, Aleksandra Majchrzak-Celińska, Szymon Tomczak, Mikołaj Baranowski, Rafał Pietrzyk, Aneta Woźniak-Braszak, Anna Jelińska

    Background/Objectives: Adult-type diffuse gliomas, including astrocytoma and glioblastoma multiforme (GBM), are brain tumors with a very poor prognosis. While current treatment options for glioma patients are not providing satisfactory outcomes, research indicates that natural compounds could serve as alternative treatments. However, their low bioavailability requires nanotechnology solutions, such as liposomes. Methods: In this study, we propose the co-encapsulation of acteoside (ACT) with other natural compounds, cannabidiol (CBD) or naringenin (NG), in a cationic liposomal nanoformulation consisting of DOTAP and POPC lipids, which were prepared using the dry lipid film method. The liposomes were characterized by their physicochemical properties, including particle size, zeta potential, and polydispersity index (PDI), with additional analyses performed using 1H Nuclear Magnetic Resonance (NMR). Furthermore, biological experiments were performed with U-87 MG astrocytoma and U-138 MG GBM cell lines and non-cancerous MRC-5 lung fibroblasts using the MTT assay and evaluating the expression of Bax and Bcl-xL to evaluate their potential as anticancer agents. Conclusions: The IC50 values for the nanoformulations in U-138 MG cells at 48 h were 6 µM for ACT + CBD and 5 µM for ACT + NG. ACT and CBD or NG demonstrated a potential synergistic effect against GBM in a liposomal formulation. Notably, treatment with ACT + CBD (5 µM) and ACT + NG (5 µM) liposomal formulations significantly upregulated Bax protein level in U-138 cells at both 24 and 48 h. In parallel, ACT + CBD (5 µM) also modulated Bcl-xL protein level in both U-138 MG and U-87 MG cell lines at the same time points. The obtained nanoformulations were homogeneous and stable for 21 days, evidenced by a narrow particle size distribution, a low polydispersity index (PDI) < 0.3, and a positive zeta potential.


  • Open Access

    Antioxidants Acteoside and Orientin as Emerging Agents in Synergistic Cancer Therapy: A Focus on Innovative Applications

    by Jagoda Szkudlarek, Ludwika Piwowarczyk, Anna Jelińska

    Cancers, particularly those resistant to treatment, stand as one of the most significant challenges in medicine. Frequently, available therapies need to be improved, underscoring the necessity for innovative treatment modalities. Over the years, there has been a resurgence of interest in natural plant substances, which have been traditionally overlooked as anticancer agents. A prime example of this is natural antioxidants, such as acteoside (ACT) and orientin (ORI), which offer novel approaches to cancer treatment, emphasizing liver cancer compared to other cancer types. They reduce oxidative stress by activating the Nrf2/ARE pathway and exhibit anticancer activity, e.g., decreasing Bcl-2 and Bcl-XL expression and increasing Bax levels. This review explores the individual effects of ACT and ORI and their synergistic interactions with sorafenib, temozolomide, 5-fluorouracil (for ACT), celecoxib, and curcumin (for ORI), highlighting their enhanced anticancer efficacy. In addition, ACT and ORI successfully integrate into various drug delivery systems (DDSs), including metal-containing carriers such as nanoparticles (NPs), nanoshells (NSs), quantum dots (QDs), and liposomes as representative examples of lipid-based drug delivery systems (LBDDSs). Advanced methods, including nanotechnology, offer potential solutions to low bioavailability, paving the way for the use of these substances in anticancer therapy.